RESULTS

- Only tigecycline (MIC50, 0.25 µg/mL) and linezolid (MIC50 and MIC90 of 2 µg/mL) were susceptible to all isolates; however, linezolid MIC50s of > 8 µg/mL were found for Enterococcus spp. (107) and Staphylococcus aureus (132). Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 4 µg/mL and MIC90s ≤ 8 µg/mL.

- All isolates were susceptible to ceftriaxone (MIC ≤ 0.016 µg/mL) and ceftazidime (MIC ≤ 0.06 µg/mL), including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- With the exception of Enterococcus spp., tigecycline was more active than quinupristin/dalfopristin (MIC50 and MIC90 of < 0.25 µg/mL), including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Tigecycline was more active than teicoplanin (MIC50 and MIC90 of ≤ 0.25 µg/mL) and vancomycin (MIC50 and MIC90 of ≤ 0.25 µg/mL), including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Ciprofloxacin was susceptible to Enterococcus spp. with MIC50s ≤ 0.12 µg/mL and MIC90s ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Azithromycin was susceptible to Enterococcus spp. with MIC50s ≤ 0.5 µg/mL and MIC90s ≤ 1 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Erythromycin was susceptible to Enterococcus spp. with MIC50s ≤ 0.12 µg/mL and MIC90s ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ciprofloxacin was common among Enterococcus spp. with MIC90s of > 16 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to azithromycin was common among Enterococcus spp. with MIC90s of > 1 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to erythromycin was common among Enterococcus spp. with MIC90s of > 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to tigecycline was uncommon among Enterococcus spp. with MIC90s of ≤ 16 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to vancomycin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to teicoplanin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to quinupristin/dalfopristin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftriaxone was uncommon among Enterococcus spp. with MIC90s of ≤ 0.06 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftazidime was uncommon among Enterococcus spp. with MIC90s of ≤ 0.12 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to vancomycin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to teicoplanin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to quinupristin/dalfopristin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftriaxone was uncommon among Enterococcus spp. with MIC90s of ≤ 0.06 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftazidime was uncommon among Enterococcus spp. with MIC90s of ≤ 0.12 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to vancomycin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to teicoplanin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to quinupristin/dalfopristin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftriaxone was uncommon among Enterococcus spp. with MIC90s of ≤ 0.06 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to ceftazidime was uncommon among Enterococcus spp. with MIC90s of ≤ 0.12 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.

- Resistance to vancomycin was uncommon among Enterococcus spp. with MIC90s of ≤ 0.25 µg/mL, including isolates from patients with suspected multidrug-resistant strains. Tigecycline was susceptible to Enterococcus spp. with MIC50s ≤ 8 µg/mL and MIC90s ≤ 16 µg/mL.